Live: Will Tonight’s Q2 Earnings Report Send Vertex Pharmaceuticals Higher?

That wraps up our initial coverage of VRTX’s Q2 results. Thank you for stopping by!

Vertex Pharmaceuticals delivered a strong Q2, with revenue rising 12% year over year to $3.33 billion, GAAP net income reaching $1.1 billion, and non-GAAP net income hitting $1.2 billion.

Its cystic fibrosis franchise remained the foundation of the business, supported by strong ALYFTREK adoption, but the bigger story was the accelerating contribution from Vertex’s newer products.

CASGEVY revenue surged 151% year over year and 78% sequentially to $76 million, while JOURNAVX generated $50 million, more than quadrupling from a year earlier and climbing 71% from Q1. Vertex now expects the two products to contribute more than $500 million in combined 2026 revenue.

Management raised its full-year revenue guidance from $12.95-$13.1 billion to a new range of $13.1-$13.2 billion, while leaving its expense outlook unchanged.

That forecast excludes the pending roughly $10 billion acquisition of Crinetics Pharmaceuticals, which is expected to close in Q3 and would establish rare endocrine diseases as another major growth pillar.

Vertex also holds $13.6 billion in cash and marketable securities and faces a November 30 PDUFA decision for povetacicept in IgA nephropathy.

The quarter strengthens the diversification thesis:

• Vertex’s CF franchise continues to grow
• CASGEVY and JOURNAVX are scaling rapidly
• The pipeline and Crinetics acquisition could add several new sources of long-term revenue

Vertex Pharmaceuticals (NASDAQ:VRTX) just reported earnings, with shares initially up 1% following the report.

Key Numbers:

• 🟢 Revenue: $3.33 billion vs. $3.22 billion expected
• 🔴 Adjusted EPS: $4.73 vs. $4.75 expected

Quick Read:

Vertex delivered a 3.4% revenue beat, with sales climbing 12% year over year.

Adjusted EPS narrowly missed expectations by $0.02, but the strong top-line result appears to be driving the initially positive reaction.

Bull Case

• CF franchise still dominates: TRIKAFTA/KAFTRIO delivered $2.35 billion last quarter, with ALYFTREK ramping to $424.4 million.
• Diversification is landing: JOURNAVX and CASGEVY drove more than 25% of Q1 growth.
• Povetacicept BLA and a 6-month expedited nephrology review offer a fresh catalyst.
• Analysts remain constructive with a $557.12 consensus target.

Bear Case

• Q1 revenue slightly missed by 0.36%, echoing prior narrow surprises.
• Pipeline turbulence: VX-522 terminated, plus insiders logged 16 net-selling transactions.
• CF still contributes over 90% of revenue, keeping concentration risk elevated.
• Shares trade at 28x trailing earnings against reaffirmed $12.95 billion to $13.10 billion guidance, leaving little room for softness.

Keep an eye on the stock into the 4:30 PM ET Q2 earnings call.

Guidance Is Everything: What Wall Street Wants to Hear

Beyond the headline numbers, the market is watching whether Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) tightens or lifts its $12.95B to $13.10B FY2026 revenue range. CEO Reshma Kewalramani’s playbook has been conservative: reiterate early, narrow upward later.

A bullish scenario: Raising the top end above $13.10B, lifting the non-CF target above $500M, and pulling forward povetacicept’s launch timeline.

A bearish read: Narrowing to the low end, holding non-CF flat, or flagging heavier opex from the nephrology build.

Investors also want color on JOURNAVX prescription momentum, CASGEVY infusion cadence, and the 19.5% to 20.5% tax rate.

Historic recap: In Q3 of 2025, shares fell 10% on a beat because guidance disappointed. Tonight, forward guidance will drive the stock’s reaction just as much as the quarter’s results themselves.

Vertex Pharmaceuticals (NASDAQ:VRTX) hosts its Q2 call at 4:30 PM ET, with shares at $471.78 and put/call skewed defensively at 1.28.

Top 5 Analyst Questions

• Pace of JOURNAVX scripts after crossing 1 million cumulative fills?
• Povetacicept BLA review timing under the 6-month expedited path?
• TRIKAFTA erosion versus ALYFTREK cannibalization?
• CASGEVY infusion cadence beyond 500 patients initiated?
• VX-828 readout expectations for H2 2026?

Key Topics to Address

• Progress toward the $500M+ non-CF revenue target
• Nephrology commercial buildout costs
• Non-GAAP tax rate holding at 19.5%-20.5%

Buzzwords to Listen For

• “Fourth franchise,” “diversified revenue base,” “Priority Review Voucher,” “formulary access,” “patient infusions”

Red Flags

• Any trim to the $12.95B-$13.10B revenue range
• JOURNAVX inventory destocking commentary
• Zimislecel manufacturing setbacks
• Rising GAAP tax rate beyond 17.7%

Vertex Pharmaceuticals enters tonight’s earnings report with investors focused on the company’s emerging growth engines.

The regulatory progress for povetacicept and the broader nephrology franchise will carry significant narrative weight, while JOURNAVX and CASGEVY must again contribute meaningful growth to validate Vertex’s diversification strategy.

The first number to check will be whether management reaffirms its full-year revenue guidance of $12.95-$13.10 billion. Vertex’s 28-times trailing earnings multiple and $557.12 consensus analyst price target assume the company can successfully layer nephrology, pain, and cell therapy revenue onto its mature cystic fibrosis franchise.

A reaffirmed outlook with visible non-CF traction would support that thesis, while a guidance cut or softer JOURNAVX results could revive concerns about the pace of diversification.